# A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05990127/  
OnCo record `nct05990127` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of cadonilimab, tislelizumab, carboplatin, pemetrexed and other drugs in lung cancer, run by Akeso, not yet recruiting.

## Summary

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05990127 by Akeso, with a registry enrolment figure of 642 participants, started 2023-11-14 and due to reach its primary completion in 2025-08-05. Interventions recorded: AK104; Tislelizumab; carboplatin; Pemetrexed; Paclitaxel. Conditions listed: Locally Advanced or Metastatic NSCLC. Primary outcome: Overall Survival(OS); Progression-Free Survival(PFS) by investigator(INV). Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or metastatic (Stage IV) NSCLC (American Joint Committee on Cancer \[AJCC\] 8th edition)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05990127
- Phase: 3
- Setting: A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Akeso
- Enrolled: 642

## Sources

- ClinicalTrials.gov NCT05990127: https://clinicaltrials.gov/study/NCT05990127

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05990127.json